Literature DB >> 24246608

Locally advanced gallbladder cancer: which patients benefit from resection?

D J Birnbaum1, L Viganò2, A Ferrero1, S Langella1, N Russolillo1, L Capussotti1.   

Abstract

OBJECTIVES: Patients with T3-4 gallbladder cancers (GBCs) often require extended surgical procedures, and up to 30% of patients have N2 metastases. This study investigated which patients with T3-4 GBC benefit from resection.
METHODS: Consecutive patients (n = 78) with T3-4 GBC who underwent resection between 1990 and 2011 were analysed (38 before 2003, 40 in 2003-2011). Forty patients required common bile duct (CBD) resection, 10 pancreatoduodenectomy, 4 right colectomy and 2 gastric resection. Fifty-two (67%) patients had LN metastases, including 22 with N2 metastases.
RESULTS: The in-hospital mortality rate was 8%, 11% before 2003 vs. 5% in 2003-2011. The morbidity rate (47%) remained stable during the study. Undergoing liver and pancreatic resection did not increase severe morbidity (0%) or mortality (10%). Sixty-seven (86%) patients had R0 resection. The 5-year survival rate was 17% (median follow-up, 65 months). Survival improved after 2002 (26% vs. 9%, p = 0.04). R1 patients had poor 3-year survival (0% vs. 32%, p = 0.001). N+ patients also had low survival (5-year survival, 10% vs. 32% in N0, p = 0.019), but N1 and N2 patients had similar outcomes. CBD resection and major hepatectomy did not worsen prognosis. Patients requiring pancreatoduodenectomy, gastric or colonic resection had 0% 3-year survival (p = 0.036 in multivariate analysis).
CONCLUSIONS: Resection of T3-4 GBC is worthwhile only if R0 surgery is achievable. Outcomes improved in most recent years. N2 metastases should not preclude surgery. Good results are possible even with CBD resection or major hepatectomy, while benefits from surgery are doubtful if pancreatoduodenectomy or other organ resection is needed.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Common bile duct resection; Gallbladder cancer resection; Liver surgery; Pancreatoduodenectomy; Prognostic factors; Survival

Mesh:

Year:  2013        PMID: 24246608     DOI: 10.1016/j.ejso.2013.10.014

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  12 in total

1.  Gallbladder cancer: expert consensus statement.

Authors:  Thomas A Aloia; Nicolas Járufe; Milind Javle; Shishir K Maithel; Juan C Roa; Volkan Adsay; Felipe J F Coimbra; William R Jarnagin
Journal:  HPB (Oxford)       Date:  2015-08       Impact factor: 3.647

Review 2.  Minireview on laparoscopic hepatobiliary and pancreatic surgery.

Authors:  Clara Tan-Tam; Stephen W Chung
Journal:  World J Gastrointest Endosc       Date:  2014-03-16

3.  Hepato-pancreatectomy: how morbid? Results from the national surgical quality improvement project.

Authors:  Thuy B Tran; Monica M Dua; David A Spain; Brendan C Visser; Jeffrey A Norton; George A Poultsides
Journal:  HPB (Oxford)       Date:  2015-06-08       Impact factor: 3.647

4.  Surgical management of biliary malignancy.

Authors:  T Peter Kingham; Victoria G Aveson; Alice C Wei; Jason A Castellanos; Peter J Allen; Daniel P Nussbaum; Yinin Hu; Michael I D'Angelica
Journal:  Curr Probl Surg       Date:  2020-06-30       Impact factor: 1.909

5.  Descriptive analysis of incidental and operable gallbladder carcinoma cases: a UK centre experience.

Authors:  Sanwandana Karunaratne; Amila Gamage; Izhar N Bagwan
Journal:  Pathologica       Date:  2022-04

6.  Long-Term Outcomes and Prognostic Factors in Advanced Gallbladder Cancer: Focus on the Advanced T Stage.

Authors:  Chen Chen; Zhimin Geng; Haoxin Shen; Huwei Song; Yaling Zhao; Guanjun Zhang; Wenzhi Li; Li Ma; Lin Wang
Journal:  PLoS One       Date:  2016-11-15       Impact factor: 3.240

7.  A phase III randomised clinical trial of perioperative therapy (neoadjuvant chemotherapy versus chemoradiotherapy) in locally advanced gallbladder cancers (POLCAGB): study protocol.

Authors:  Reena Engineer; Shraddha Patkar; Shirley Christabel Lewis; Ashutosh Das Sharma; Nitin Shetty; Vikas Ostwal; Anant Ramaswamy; Supriya Chopra; Archi Agrawal; Prachi Patil; Shaesta Mehta; Mahesh Goel
Journal:  BMJ Open       Date:  2019-06-27       Impact factor: 2.692

8.  A new nomogram from the SEER database for predicting the prognosis of gallbladder cancer patients after surgery.

Authors:  Zunqiang Xiao; Zhan Shi; Linjun Hu; Yuling Gao; Junjun Zhao; Yang Liu; Qiuran Xu; Dongsheng Huang
Journal:  Ann Transl Med       Date:  2019-12

9.  Development and validation of a nomogram for survival benefit of lymphadenectomy in resected gallbladder cancer.

Authors:  Mingyu Chen; Jian Lin; Jiasheng Cao; Hepan Zhu; Bin Zhang; Angela Wu; Xiujun Cai
Journal:  Hepatobiliary Surg Nutr       Date:  2019-10       Impact factor: 7.293

10.  Who benefits from R0 resection? A single-center analysis of patients with stage Ⅳ gallbladder cancer.

Authors:  Chen Chen; Lin Wang; Rui Zhang; Qi Li; Ya-Ling Zhao; Guan-Jun Zhang; Wen-Zhi Li; Zhi-Min Geng
Journal:  Chronic Dis Transl Med       Date:  2019-10-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.